Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimetazidine - Servier

Drug Profile

Trimetazidine - Servier

Alternative Names: Adexor; Flavedon; Idaptan; Preductal; S 5016; Trimetazine; Vastarel; Vastarel F; Vastinan

Latest Information Update: 18 Jul 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Class Anti-ischaemics; Cytoprotectives; Hepatoprotectants; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Adenosine triphosphatase inhibitors; Antioxidants; Calcium channel antagonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Eye disorders; Ischaemic heart disorders; Tinnitus; Vertigo

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 22 Jun 2012 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that trimetazidine is not used for treatment of vertigo, tinnitus or vision disturbance, and the deletion of these indications from the marketing authorisation .
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top